Pharmaceutical QMS software — one platform for documents, training, CAPA, change, and audits.
V5 is the electronic quality management system for FDA- and EMA-regulated pharma — document control, training, deviation, CAPA, change control, audits, supplier quality, complaints — running on one Part 11 / Annex 11 architecture with the validation pack included.
What breaks without this.
Six systems, one quality function
Documents in SharePoint, training in an LMS, CAPA in TrackWise, deviation in spreadsheets, complaints in a CRM. Auditors trace one finding and the chain breaks.
Change control doesn't reach the floor
An SOP changes, the training reassigns, the equipment qualification status updates — but the operator at the kiosk doesn't see it. The next batch runs old.
Complaint, deviation, and CAPA live apart
Same root cause, three different records, no aggregation. Trend analysis is a quarterly project, not a live view.
Records-by-execution. Compliance, by design.
One quality chain, end to end
Document, training, deviation, CAPA, change, audit, supplier, complaint — one platform, one numbering, one audit trail.
Change control that reaches the kiosk
A controlled document revision triggers training reassignment and locks the relevant kiosk steps until operators re-train. No silent drift.
Trending built in
Deviations, CAPAs, complaints, OOS, OOT — trended by product, line, root cause, and supplier. Quality reviews are live dashboards, not slide decks.
ICH Q10 + Part 11 + Annex 11
Designed for global pharma — same architecture passes FDA, EMA, MHRA, PMDA, ANVISA.
What to look for when you're buying.
Pharmaceutical QMS is a category dense with sales noise. These criteria separate a real eQMS from a CRUD app with the right module names.
All ten elements integrated
What it tests: Do documents, training, CAPA, change, deviation, complaint, supplier, audit, management review, and risk live on one record set?
Why it matters: Multi-module QMS suites with separate databases lose integrity at the seams.
V5: All ten elements share one record set with consistent audit trail and genealogy.
Records-execution integration
What it tests: Does the QMS see what is happening on the floor — or only what was reported afterwards?
Why it matters: QMS detached from MES is the dominant reason QMS data lags reality.
V5: Same platform runs MES, WMS, QMS — QMS sees execution in real time.
ICH Q10 lifecycle awareness
What it tests: Does the system recognize pharmaceutical lifecycle as state — not just stage labels?
Why it matters: Q10 expects controls to scale with lifecycle.
V5: Lifecycle is data; controls and signature flows adjust per state.
Document control with training linkage
What it tests: Does a document revision auto-assign training and lock the floor until current?
Why it matters: Doc-to-training disconnect is one of the most common 211.25 findings.
V5: Revision triggers training reassignment and kiosk lockout for non-current operators.
Change control with risk-driven scope
What it tests: Is change control risk-driven with scope across process, equipment, supplier, regulatory, and validation impact?
Why it matters: Single-dimension change control misses cross-impact.
V5: Change control assesses scope across all five impact dimensions automatically.
Audit-to-CAPA closed loop
What it tests: Do audit findings auto-route to CAPA with severity-driven SLA?
Why it matters: Audit findings stranded in PDFs are the most common 'open audit' finding in the next audit.
V5: Findings auto-route to CAPA with severity, owner, SLA — and gate effectiveness.
Management review as live data
What it tests: Is management review a live dashboard — not a slide deck?
Why it matters: Q10 §3.2.4 expects management review as a process, not an event.
V5: Live dashboards aggregate QMS, MES, and supplier data; the review meeting walks live data.
Annex 11 + Part 11 + ICH Q10 in one footprint
What it tests: Does the same architecture satisfy FDA, EMA, MHRA, PMDA, and ICH-aligned regulators?
Why it matters: Multi-region pharma cannot afford one QMS per region.
V5: One architecture, multi-regulator outputs.
Spreadsheet vs legacy QMS vs V5.
How V5 eQMS compares to typical alternatives.
| Capability | Spreadsheet | Legacy QMS | V5 Ultimate |
|---|---|---|---|
| Integrated record set | Module silos | Multi-module suite | One record set |
| MES integration | None | Interface project | Native |
| Doc → training lockout | Manual | Separate LMS | Automatic |
| Change control scope | Manual | Partial | Five-dimension auto-scope |
| Audit → CAPA loop | Linked | Auto-routed, SLA, effectiveness gate | |
| Management review | Slide deck | Quarterly PDF | Live dashboard |
| Multi-region coverage | Multiple sets | Often US-only | FDA/EMA/PIC/S/ICH in one |
| Time to deploy | Day 1 | 9-18 months | 21-30 days |
The clauses, verbatim — and how V5 answers each.
The clauses pharmaceutical inspectors weigh most.
The PQS should be applicable throughout the product lifecycle…
V5: Lifecycle state drives controls; development, transfer, commercial, and discontinuation states are first-class in V5.
Process performance and product quality monitoring system.
V5: Live monitoring from MES feeds the QMS; trending is continuous, not retrospective.
Corrective action and preventive action (CAPA) system.
V5: Forced source-record linkage and effectiveness verification; covered in detail in V5 CAPA pillar.
Change management system.
V5: Five-dimension impact scoping; change-driven re-validation, training reassignment, and supplier requalification fire automatically.
Management review of process performance and product quality.
V5: Live dashboards anchor management review as a continuous process.
Written records… shall be maintained so that data therein can be used for evaluating, at least annually, the quality standards of each drug product.
V5: Annual product quality review (PQR / APR) generates from the live record set.
A Pharmaceutical Quality System… should incorporate Good Manufacturing Practice and Quality Risk Management.
V5: PQS, GMP, and QRM share one record set in V5; risk artifacts link directly to controls.
Validated electronic records and signatures.
V5: Architecture-level compliance covered in the Part 11 pillar.
Step by step on the floor.
Pharmaceutical QMS on V5 across a quarter.
- 1Daily
Floor execution feeds QMS
MES execution writes directly to QMS records; deviations open at the kiosk; supplier non-conformances route from receiving.
- 2Weekly
Document and training drift caught
Revisions trigger training reassignment; non-current operators are locked out at the kiosk until current.
- 3Monthly
Change control scoped
Change records auto-scope across process, equipment, supplier, regulatory, and validation; review meeting walks live impact.
- 4Per audit
Findings auto-route to CAPA
Internal and external audit findings emit CAPAs with severity-driven SLA; effectiveness gated at closure.
- 5Quarterly
Management review on live data
Q10 §3.2.4 management review opens with the live dashboard; decisions emit as documented actions in the same record set.
- 6Annually
APR derived, not assembled
Annual Product Review derives from the live record set; the document is a one-click export, not a four-week project.
The math, with the assumptions visible.
Pharma eQMS ROI is dominated by audit posture, deviation reduction, and APR labor.
Audit observations on QMS subsystems
Gating at the step removes the most-cited categories.
APR / PQR labor
APR is derived from the live record set.
Cross-module reconciliation labor
One record set eliminates the seams.
Time to deploy new site on QMS
Standard onboarding includes data migration, training, and validation handoff.
Pharma eQMS payback is typically dominated by APR labor and audit posture; many sites recoup V5 inside two quarters.
What changed on the floor.
Setting
A mid-cap pharma with 6 sites running a legacy multi-module QMS suite with separate LMS and CMMS.
Before
QMS data lagged MES execution by 24-72 hours. APR averaged 280 hours per product per year. Three of six sites had open audit findings on §211.25 training-doc disconnect.
After
Twelve months after V5 cutover at the lead site: QMS records contemporaneous with execution, APR labor under 30 hours per product, training-doc findings closed at the next inspection cycle, and the next two sites cutover in 28 and 31 days respectively.
Proof points
- One audit trail across documents, training, CAPA, change, complaint
- Change control reaches the kiosk — no silent drift
- Live trending — quality review is a dashboard, not a slide deck
- Validation pack included — IQ/OQ/PQ regenerated each release
Built to satisfy
- 21 CFR 210 / 211 (cGMP for finished pharmaceuticals)
- 21 CFR Part 11 (electronic records & signatures)
- EU GMP Part I (medicinal products) + Annex 11
- ICH Q7 (APIs), Q8 (development), Q9 (risk), Q10 (PQS)
- PIC/S PI 011
Frequently asked questions
What modules does the V5 pharma QMS include?+
Document control, training & skills matrix, deviation, CAPA, change control, internal & external audits, supplier quality, complaints, and annual product review — all on one Part 11 / Annex 11 platform.
Is V5 aligned with ICH Q10?+
Yes. V5 implements the four ICH Q10 elements — process performance & product quality monitoring, CAPA, change management, and management review — as live, interconnected workflows rather than separate logs.
Does V5 support multi-site, multi-country pharma operations?+
Yes. One tenant can host multiple sites with site-specific SOPs, training matrices, and document hierarchies — while quality leadership sees aggregated trending across the network.
What about validation?+
The IQ/OQ/PQ pack and regression test suite ship with V5 and are re-issued on every release. Customers run a delta — not a full re-validation.
See V5 on your own line.
Free trial, no card. Live in 7 days with guided onboarding.